EyePoint, Inc. (EYPT)
0.4045
-0.02
(-5.51%)
USD |
NASDAQ |
Oct 23, 16:00
0.413
+0.01
(+2.10%)
After-Hours: 20:00
EyePoint Enterprise Value : -123.73M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -123.73M |
| October 22, 2026 | -121.72M |
| October 21, 2026 | -121.56M |
| October 20, 2026 | -123.67M |
| October 19, 2026 | -120.71M |
| October 16, 2026 | 95.99M |
| October 15, 2026 | 108.74M |
| October 14, 2026 | 97.69M |
| October 13, 2026 | 102.79M |
| October 12, 2026 | 124.03M |
| October 09, 2026 | 130.83M |
| October 08, 2026 | 135.93M |
| October 07, 2026 | 124.03M |
| October 06, 2026 | 111.29M |
| October 05, 2026 | 109.59M |
| October 02, 2026 | 118.09M |
| October 01, 2026 | 116.39M |
| September 30, 2026 | 119.79M |
| September 29, 2026 | 132.53M |
| September 28, 2026 | 123.18M |
| September 25, 2026 | 149.53M |
| September 24, 2026 | 152.08M |
| September 23, 2026 | 158.03M |
| September 22, 2026 | 187.77M |
| September 21, 2026 | 183.52M |
| Date | Value |
|---|---|
| September 18, 2026 | 169.07M |
| September 17, 2026 | 180.97M |
| September 16, 2026 | 135.08M |
| September 15, 2026 | 152.93M |
| September 14, 2026 | 203.07M |
| September 11, 2026 | 201.37M |
| September 10, 2026 | 203.07M |
| September 09, 2026 | 210.72M |
| September 08, 2026 | 229.41M |
| September 04, 2026 | 231.11M |
| September 03, 2026 | 229.84M |
| September 02, 2026 | 248.96M |
| September 01, 2026 | 231.11M |
| August 31, 2026 | 224.31M |
| August 28, 2026 | 222.61M |
| August 27, 2026 | 235.36M |
| August 26, 2026 | 265.95M |
| August 25, 2026 | 267.23M |
| August 24, 2026 | 255.76M |
| August 21, 2026 | 294.00M |
| August 20, 2026 | 300.80M |
| August 19, 2026 | 377.28M |
| August 18, 2026 | 306.75M |
| August 17, 2026 | 255.76M |
| August 14, 2026 | 1.095B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ocular Therapeutix, Inc. | 908.07M |
| Regeneron Pharmaceuticals, Inc. | 77.94B |
| Corcept Therapeutics, Inc. | 8.967B |
| Eli Lilly & Co. | 1.245T |
| Nuvation Bio, Inc. | 1.354B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -94.47M |
| Revenue (Quarterly) | 0.507M |
| Total Expenses (Quarterly) | 94.98M |
| EPS Diluted (Quarterly) | -1.092 |
| Gross Profit Margin (Quarterly) | -36.09% |
| Profit Margin (Quarterly) | -18.63K% |
| Earnings Yield | -925.5% |
| Normalized Earnings Yield | -925.49 |